<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glycemic control and vascular complications in type 2 diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glycemic control and vascular complications in type 2 diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Glycemic control and vascular complications in type 2 diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Silvio E Inzucchi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beatrice Lupsa, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The importance of intensive glycemic control for protection against microvascular and cardiovascular disease (CVD) in diabetes was established for type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study [<a href="#rid1">1,2</a>]. Although the benefit of glycemic control on microvascular disease in type 2 diabetes was documented in the United Kingdom Prospective Diabetes Study (UKPDS), its role in reducing cardiovascular risk has not been similarly established.</p><p>Glycemic targets and the effects of glycemic control on microvascular and macrovascular complications in type 2 diabetes will be reviewed here. Glycemic control and vascular complications in type 1 diabetes, the mechanism by which hyperglycemia might cause these complications, and an overview of the treatment of diabetes are discussed separately. (See  <a class="medical medical_review" href="/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H726886753"><span class="h1">CHOOSING A GLYCEMIC TARGET</span><span class="headingEndMark"> — </span>Selecting an appropriate target glycated hemoglobin (A1C; intensive versus moderate control) should be individualized based upon comorbid conditions and functional status, balancing the potential benefit of improved glycemic control with the risks of hypoglycemia and weight gain. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most patients</strong> – A reasonable goal of therapy for most patients might be an A1C value of &lt;7 percent (using a Diabetes Control and Complications Trial [DCCT]/United Kingdom Prospective Diabetes Study [UKPDS]-aligned assay in which the upper limit of normal is 6 percent). In order to achieve the A1C goal, a fasting glucose of 80 to 130 mg/dL (4.4 to 7.2 mmol/L) and a postprandial glucose (90 to 120 minutes after a meal) less than 180 mg/dL (10 mmol/L) have been given as targets, but higher achieved levels may suffice  (<a class="graphic graphic_table graphicRef121967" href="/d/graphic/121967.html" rel="external">table 1</a>) [<a href="#rid3">3,4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older patients or those with complications or comorbidities</strong> – The A1C goal should be set somewhat higher (eg, &lt;8 percent or higher) for patients with a history of severe hypoglycemia, patients with limited life expectancy, very young children or older adults, and individuals with advanced complications or comorbid conditions.</p><p></p><p>Improved glycemic control lowers the risk of microvascular complications in patients with type 2 diabetes  (<a class="graphic graphic_figure graphicRef52273" href="/d/graphic/52273.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef126680" href="/d/graphic/126680.html" rel="external">table 2</a>) [<a href="#rid5">5-12</a>]. However, the absolute risk for microvascular complications and the incremental benefit of intensively lowering A1C must be balanced against the diminishing returns and the heightened risk of hypoglycemia at A1C levels less than 6.5 percent. (See <a class="local">'Microvascular disease'</a> below.)</p><p>Only limited clinical trial data (the long-term follow-up of the UKPDS) has demonstrated a macrovascular benefit with intensive therapy in patients with newly diagnosed type 2 diabetes [<a href="#rid6">6</a>]. The results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial suggest that a target A1C of 7.0 to 7.9 percent (achieving a median of 7.5 percent) may be safer for patients with longstanding type 2 diabetes and who are at high risk for cardiovascular disease (CVD) than a target A1C of less than 6.0 percent (achieving a median of 6.4 percent) [<a href="#rid7">7</a>]. (See <a class="local">'Macrovascular disease'</a> below.)</p><p>A target of 7.0 to 7.9 percent is also supported by the results of a retrospective cohort study of approximately 48,000 patients with type 2 diabetes, aged 50 years and older, whose treatment had been intensified [<a href="#rid13">13</a>]. After a mean follow-up of approximately 4.5 years, all-cause mortality was highest in those with the lowest (less than 6.7 percent) and highest (9.9 percent) A1C values. An A1C level of 7.5 percent was associated with the lowest all-cause mortality. Similar findings were reported in a population-based cohort study of patients with diabetes and chronic kidney disease (estimated glomerular filtration rate [eGFR] 15 to 59.9 mL/min/1.73 m<sup>2</sup>) [<a href="#rid14">14</a>]. There was a U-shaped relationship between A1C and mortality, with risk of mortality increasing with A1C values below 6.5 or above 8 percent.</p><p>All guidelines recommend tailoring A1C goals for individual patients. The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus algorithm recommend an A1C of less than 7 percent for most nonpregnant adults due to the benefits of reducing microvascular complications [<a href="#rid4">4,15</a>]. The American College of Physicians recommends an A1C between 7 and 8 percent [<a href="#rid16">16</a>]. The American Geriatrics Society suggests an A1C target of 8 percent for frail older adults and individuals with life expectancy of less than five years. These recommendations are supported by a decision analysis integrating multiple prediction models [<a href="#rid17">17</a>]. In this analysis, comorbid conditions and functional impairment were better predictors of both life expectancy and less benefit from intensive glucose control than age alone. (See  <a class="medical medical_review" href="/d/html/1776.html" rel="external">"Treatment of type 2 diabetes mellitus in the older patient"</a>.)</p><p class="headingAnchor" id="H2422587862"><span class="h1">INTENSIVE GLYCEMIC CONTROL</span></p><p class="headingAnchor" id="H1796327788"><span class="h2">Benefits</span></p><p class="headingAnchor" id="H266194121"><span class="h3">Microvascular disease</span><span class="headingEndMark"> — </span>Improved glycemic control lowers the risk of microvascular complications in patients with type 2 diabetes (primarily retinopathy, nephropathy) as illustrated by the findings of the United Kingdom Prospective Diabetes Study (UKPDS), Kumamoto, Action in Diabetes and Vascular Disease (ADVANCE), and Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials  (<a class="graphic graphic_table graphicRef126680" href="/d/graphic/126680.html" rel="external">table 2</a>) [<a href="#rid5">5-11</a>]. In a meta-analysis of these and other randomized trials (34,912 participants), there was a reduction in the risk of microvascular complications (a composite outcome including progression of nephropathy, manifestation and progression of retinopathy, and retinal photocoagulation) in the intensive compared with standard glycemic control group (risk ratio [RR] 0.88, 95% CI 0.82-0.95) [<a href="#rid18">18</a>]. There were significant reductions in risk for each of the individual components. </p><p>In other meta-analyses of trials (over 28,000 adults) evaluating the benefits of intensive versus conventional glycemic control specifically on renal outcomes, there was a statistically significant reduction in the risk of microalbuminuria and macroalbuminuria in patients randomly assigned to intensive glycemic control (RRs of 0.86 and 0.74, respectively) [<a href="#rid19">19-21</a>]. The reduction in risk of end-stage kidney disease did not reach statistical significance (RR 0.69, 95% CI 0.46-1.05). There was no reduction in the risk of doubling of the serum creatinine level or death from renal disease (RRs 1.06 and 0.99, respectively) [<a href="#rid20">20</a>]. Of note, the majority of the trials in the meta-analyses were not of long enough duration to show a beneficial effect of glycemic control on end-stage kidney disease, which typically manifests after 10 to 20 years of diabetes duration [<a href="#rid22">22</a>]. In the trials included in the meta-analyses, the absolute rates of severe renal outcomes were low in both the intensive therapy and conventional therapy groups, reducing the ability of the analysis to demonstrate a benefit, if one exists. In the one trial with longer-term follow-up (UKPDS cohort followed for 22 years), there was a beneficial effect of intensive therapy on the development of more advanced clinical outcomes, including renal disease [<a href="#rid6">6</a>].</p><p>The importance of glycemic control in reducing the risk of microvascular disease is not disputed (although intensive compared with moderate glycemic control is debated) [<a href="#rid23">23</a>]. In UKPDS, every 1 percent decrease in A1C was associated with improved outcomes over the long term with no threshold effect  (<a class="graphic graphic_figure graphicRef52273" href="/d/graphic/52273.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]. In addition, the results of the post-trial monitoring phase of the UKPDS (median follow-up 17 years) showed that a sustained period of glycemic control in newly diagnosed patients with type 2 diabetes has lasting benefit in reducing microvascular disease [<a href="#rid6">6</a>]. The reduction in microvascular complications in patients receiving intensive therapy was of a smaller magnitude than in patients with type 1 diabetes in the Diabetes Control and Complications Trial (DCCT) [<a href="#rid1">1</a>]. One possible explanation for this difference is that the difference in A1C values was smaller between the intensive and conventional therapy groups in UKPDS (7.0 versus 7.9 percent) compared with the DCCT (7.2 versus 9.1 percent).</p><p>The lack of overall benefit of intensive control in the Veterans Affairs Diabetes Trial (VADT) on microvascular outcomes (although there were consistent, significant benefits with regard to albuminuria) may be secondary to the duration of diabetes in patients participating in VADT (mean 11.5 years versus newly diagnosed in UKPDS) and the time required to show benefit (delayed benefit may require longer follow-up) [<a href="#rid24">24</a>]. In addition, aggressive treatment of hypertension and hyperlipidemia in all VADT participants may have contributed to the inability to show a microvascular benefit of intensive glucose control.</p><p class="headingAnchor" id="H9"><span class="h3">Macrovascular disease</span><span class="headingEndMark"> — </span>Although epidemiologic analyses (observational studies or secondary analyses of trials) suggest a correlation between higher rates of cardiovascular disease (CVD) and chronic hyperglycemia [<a href="#rid25">25-30</a>], most randomized clinical trials have not demonstrated a beneficial effect of intensive therapy on macrovascular outcomes in type 2 diabetes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Longstanding diabetes</strong> – The VADT, ACCORD, and ADVANCE trials were designed to study the effects of intensive versus conventional therapy (achieved A1C levels of approximately 6.5 compared with 7.5 to 8.5 percent) on cardiovascular outcomes in patients with <strong>longstanding</strong> diabetes (duration 8 to 12 years) [<a href="#rid7">7,9-11,24,31,32</a>]. None show a benefit of intensive control, and results from ACCORD showed a significant increase in total (hazard ratio [HR] 1.22) and CVD (HR 1.35) mortality with intensive therapy  (<a class="graphic graphic_table graphicRef126681" href="/d/graphic/126681.html" rel="external">table 3</a>) [<a href="#rid7">7,31,33,34</a>]. Of note, ACCORD aimed for an A1C &lt;6 percent, used as many as five diabetes medications to reach its glycemic goals, and secondary analyses did not identify lower A1C or hypoglycemia as risk factors for the excess mortality in the intensive intervention group [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Newly diagnosed diabetes</strong> – In contrast to these trials, the UKPDS was designed to investigate the role of glycemic control (achieved mean A1C values of 7.0 versus 7.9 percent) on the complications of diabetes in <strong>newly diagnosed</strong> patients [<a href="#rid5">5</a>]. The UKPDS post-interventional study showed a benefit of initial intensive glycemic control (to achieve an A1C of 7 percent) on CVD in these individuals [<a href="#rid6">6</a>]. During the entire follow-up period (approximately 17 years), there were fewer overall deaths (RRs 0.87 [95% CI 0.79-0.96] and 0.73 [95% CI 0.59-0.89]), diabetes-related deaths (RRs 0.83 [95% CI 0.73-0.96] and 0.70 [95% CI 0.53-0.92]), and myocardial infarction (RRs 0.85 [95% CI 0.74-0.97] and 0.67 [95% CI 0.51-0.89]) in patients who were initially assigned to intensive treatment with sulfonylurea-insulin or <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, respectively, compared with those assigned to conventional therapy [<a href="#rid6">6</a>]. In the UKPDS, the use of nonglycemic interventions recognized to reduce CVD was less frequent, and follow-up was longer than in the other trials. In a subsequent trial (metformin versus placebo added to insulin therapy) with achieved mean glucose control similar to the UKPDS (achieved mean A1C 7.5 versus 7.9 percent), there was also a decrease in the risk of the secondary macrovascular endpoint, which was a composite of 13 vascular events including myocardial infarction, heart failure, stroke, amputation, and sudden death (event rates 15 versus 18 percent, adjusted HR 0.6 [95% CI 0.4-0.9]) [<a href="#rid37">37</a>].</p><p></p><p>In meta-analyses including UKPDS, VADT, ACCORD, ADVANCE, there was a reduction in the risk for coronary heart disease (eg, RR 0.89 [95% CI 0.81-0.96]) and nonfatal myocardial infarction (RR 0.84 [95% CI 0.75-0.94]) with intensive glucose-lowering versus standard treatment [<a href="#rid38">38-40</a>]. However, intensive treatment did not significantly affect stroke, all-cause, or cardiovascular mortality [<a href="#rid18">18,38-40</a>]. These findings differ from the results of the individual trials (VADT, ACCORD, ADVANCE) and are likely related to differences in study design, including choice of pharmacologic therapy, baseline glycemic control, and frequency of hypoglycemia  (<a class="graphic graphic_table graphicRef126681" href="/d/graphic/126681.html" rel="external">table 3</a>). As an example, in the intensively treated arm of the ACCORD trial, more than 90 percent of participants were treated with <a class="drug drug_general" data-topicid="10249" href="/d/drug information/10249.html" rel="external">rosiglitazone</a> and 77 percent were taking insulin, whereas in the ADVANCE trial, all patients in the intensive-treatment cohort were assigned to a sulfonylurea, and thiazolidinediones and insulin were used in only 16 and 40 percent, respectively. In VADT, insulin use (90 and 74 percent, respectively) and rosiglitazone use (72 and 62 percent, respectively) were common in both the intensive and standard groups. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> use was high among all patients in both ACCORD and ADVANCE (94 and 73 percent, respectively, in intensively treated patients).</p><p>Median baseline A1C was higher in VADT than in ACCORD and ADVANCE (9.4, 8.1, and 7.2 percent, respectively). A1C values were rapidly lowered during the first four months of the ACCORD trial, and there was a greater difference between the intensive and standard groups with regards to hypoglycemic events and weight gain.</p><p class="headingAnchor" id="H444737895"><span class="h2">Risks</span></p><p class="headingAnchor" id="H614180155"><span class="h3">Hypoglycemia and weight gain</span><span class="headingEndMark"> — </span>Intensive treatment of blood glucose is associated with an increased risk of hypoglycemia [<a href="#rid18">18</a>], as well as accompanying burdens of polypharmacy, additional side effects, and cost (see  <a class="medical medical_review" href="/d/html/1805.html" rel="external">"Hypoglycemia in adults with diabetes mellitus", section on 'Magnitude of the problem'</a>). Depending on the agents prescribed, weight gain may also be an adverse effect of intensive treatment  (<a class="graphic graphic_table graphicRef126681" href="/d/graphic/126681.html" rel="external">table 3</a>). In UKPDS, patients in the intensive therapy group had more weight gain; weight gain was greater in those receiving insulin (4.0 kg) than in those receiving chlorpropamide (2.6 kg) or glibenclamide (1.7 kg) [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H4061730911"><span class="h1">MULTIFACTORIAL RISK REDUCTION</span><span class="headingEndMark"> — </span>The most effective approach for prevention of macrovascular complications appears to be multifactorial risk factor reduction (glycemic control, stopping smoking, aggressive blood pressure control, treatment of dyslipidemia, and, for secondary prevention, daily <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) (see  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Multifactorial risk factor reduction'</a>). In addition, for patients with CVD, the actual type of glucose-lowering medication used has a more substantive effect on CVD risk (and, in some circumstances, renal risk) than might be expect from the degree of glucose lowering itself. Specifically, the sodium-glucose co-transporter 2 (SGLT2) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists, and, perhaps to a lesser extent, the thiazolidinedione <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a>, have been associated with reduced incidence of major adverse cardiovascular events, mainly in individuals with preexisting CVD. The SGLT2 inhibitors also appear to reduce adverse heart failure outcomes and the progression of chronic kidney disease, and this benefit applies to both those with and without CVD. In contrast, pioglitazone increases heart failure risk. Importantly, these effects appear to be independent of the effect of these agents on A1C. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p class="headingAnchor" id="H3758916948"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15751.html" rel="external">"Patient education: The ABCs of diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15402.html" rel="external">"Patient education: Type 2 diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1743.html" rel="external">"Patient education: Type 2 diabetes: Overview (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1744.html" rel="external">"Patient education: Glucose monitoring in diabetes (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1741.html" rel="external">"Patient education: Preventing complications from diabetes (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic targets</strong> –<strong> </strong>Glycated hemoglobin (A1C) goals in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. A reasonable goal of therapy might be an A1C value of ≤7 percent for most patients (using an assay in which the upper limit of normal is 6 percent). Glycemic targets are generally set somewhat higher (eg, &lt;8 percent or higher) for patients with a history of severe hypoglycemia, patients with limited life expectancy, very young children or older adults, and individuals with comorbid conditions. (See <a class="local">'Choosing a glycemic target'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microvascular disease</strong> – Improved glycemic control improves the risk of microvascular complications in patients with type 2 diabetes  (<a class="graphic graphic_table graphicRef126680" href="/d/graphic/126680.html" rel="external">table 2</a>). (See <a class="local">'Microvascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macrovascular disease</strong> –<strong> </strong>Randomized clinical trials have not demonstrated a beneficial effect of intensive therapy on macrovascular outcomes in patients with <strong>longstanding</strong> type 2 diabetes  (<a class="graphic graphic_table graphicRef126681" href="/d/graphic/126681.html" rel="external">table 3</a>). In contrast, the results of the United Kingdom Prospective Diabetes Study (UKPDS) post-trial, observational follow-up study suggest that initial intensive control (A1C 7 percent) in individuals with <strong>newly diagnosed</strong> diabetes may have long-term benefit in decreasing the risk of myocardial infarction, diabetes-related death, and overall death. (See <a class="local">'Macrovascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia risk</strong> –<strong> </strong>Intensive treatment of blood glucose is associated with an increased risk of hypoglycemia, as well as accompanying burdens of polypharmacy, additional side effects, and cost. Depending on the agents prescribed, weight gain may also occur with intensive treatment. (See <a class="local">'Hypoglycemia and weight gain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multifactorial risk factor reduction</strong> –<strong> </strong>The most effective approach for prevention of macrovascular complications appears to be multifactorial risk factor reduction (glycemic control, stopping smoking, aggressive blood pressure control, treatment of dyslipidemia, and, for secondary prevention, daily <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>). In addition, for patients with cardiovascular disease (CVD), the actual type of glucose-lowering medication used has a more substantive effect on CVD risk (and, in some circumstances, renal risk) than might be expect from the degree of glucose lowering itself. (See <a class="local">'Multifactorial risk reduction'</a> above and  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Multifactorial risk factor reduction'</a>.)</p><p></p><p class="headingAnchor" id="H674238405"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977.</a></li><li><a class="nounderline abstract_t">Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.</a></li><li><a class="nounderline abstract_t">Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care 2014; 37:1048.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S111.</a></li><li><a class="nounderline abstract_t">Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.</a></li><li><a class="nounderline abstract_t">Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577.</a></li><li><a class="nounderline abstract_t">Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376:419.</a></li><li><a class="nounderline abstract_t">Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103.</a></li><li><a class="nounderline abstract_t">ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560.</a></li><li><a class="nounderline abstract_t">Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392.</a></li><li><a class="nounderline abstract_t">ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.</a></li><li><a class="nounderline abstract_t">Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes &amp; Aging Study). Diabetes Care 2019; 42:416.</a></li><li><a class="nounderline abstract_t">Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375:481.</a></li><li><a class="nounderline abstract_t">Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171:1920.</a></li><li><a class="nounderline abstract_t">Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65:1925.</a></li><li><a class="nounderline abstract_t">Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med 2018; 168:569.</a></li><li><a class="nounderline abstract_t">Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008; 149:11.</a></li><li><a class="nounderline abstract_t">Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; :CD008143.</a></li><li><a class="nounderline abstract_t">Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5:431.</a></li><li><a class="nounderline abstract_t">Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012; 172:761.</a></li><li><a class="nounderline abstract_t">Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017; 6:CD010137.</a></li><li><a class="nounderline abstract_t">Nathan DM. Understanding the long-term benefits and dangers of intensive therapy of diabetes. Arch Intern Med 2012; 172:769.</a></li><li><a class="nounderline abstract_t">Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ 2019; 367:l5887.</a></li><li><a class="nounderline abstract_t">Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129.</a></li><li><a class="nounderline abstract_t">Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141:413.</a></li><li><a class="nounderline abstract_t">Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43:960.</a></li><li><a class="nounderline abstract_t">Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421.</a></li><li><a class="nounderline abstract_t">Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800.</a></li><li><a class="nounderline abstract_t">Selvin E, Coresh J, Golden SH, et al. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care 2005; 28:1965.</a></li><li><a class="nounderline abstract_t">Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. Am J Med 1997; 102:38.</a></li><li><a class="nounderline abstract_t">Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.</a></li><li><a class="nounderline abstract_t">Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med 2019; 380:2215.</a></li><li><a class="nounderline abstract_t">ACCORD Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364:818.</a></li><li class="breakAll">The National Heart, Lung, and Blood Institute. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Questions and Answers about the ACCORD Trial. http://www.nhlbi.nih.gov/health/prof/heart/other/accord/ (Accessed on February 14, 2008).</li><li><a class="nounderline abstract_t">Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33:983.</a></li><li><a class="nounderline abstract_t">Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340:b4909.</a></li><li><a class="nounderline abstract_t">Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169:616.</a></li><li><a class="nounderline abstract_t">Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765.</a></li><li><a class="nounderline abstract_t">Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151:394.</a></li><li><a class="nounderline abstract_t">Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343:d4169.</a></li></ol></div><div id="topicVersionRevision">Topic 1760 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8366922" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371630" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24513588" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Empirically establishing blood glucose targets to achieve HbA1c goals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078586" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742976" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784090" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 10-year follow-up of intensive glucose control in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20594588" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7587918" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539916" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234206" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587587" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of medical therapies on retinopathy progression in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30104301" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes&amp;Aging Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20110121" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123800" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36151309" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507945" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591633" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24214280" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28365411" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22636820" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28594069" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glucose targets for preventing diabetic kidney disease and its progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22636821" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Understanding the long-term benefits and dangers of intensive therapy of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31690574" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Benefits and harms of intensive glycemic control in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092145" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Glucose control and vascular complications in veterans with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381514" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039603" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : NIDDM and its metabolic control predict coronary heart disease in elderly subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381515" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200384" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043740" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209199" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539917" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of intensive glucose lowering in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31167051" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21366473" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term effects of intensive glucose lowering on cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21366473" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term effects of intensive glucose lowering on cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427682" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061358" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307526" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19465231" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620144" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Systematic review: glucose control and cardiovascular disease in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791495" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
